AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31438878 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) as second line therapy in observational cohort
Number of subjects: 26
Study 31438878 — intervention group
Group type: COMPARATOR
Intervention: No MgSO4 in observational cohort
Number of subjects: 26
Study 28438473 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (15 mg/kg every 3 weeks)
Number of subjects: 674
Study 28438473 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (paclitaxel 175 mg/m2 and carboplatin AUC 5)
Number of subjects: 674
Study 28438473 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab
Number of subjects: 674
Study 28438473 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 674
Study 25940759 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold Silk Sericin complex
Number of subjects: 40
Study 25940759 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 40
Study 23175723 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tissue plasminogen activator (tPA)
Number of subjects: 624
Study 23175723 — intervention group
Group type: COMPARATOR
Intervention: No tPA
Number of subjects: 624
Study 21937360 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito
Number of subjects: 11
Study 19377755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 35 mg/Kg/day (maximum 1200 mg/day) for three months
Number of subjects: 18
Study 19377755 — intervention group
Group type: COMPARATOR
Intervention: Zinc sulphate 10 mg/Kg/day (maximum 600 mg/day) for three months
Number of subjects: 18
Study 17617271 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC125 (200 mg) twice daily with darunavir-ritonavir and other antiretrovirals
Number of subjects: 591
Study 17617271 — intervention group
Group type: COMPARATOR
Intervention: Placebo with darunavir-ritonavir and other antiretrovirals
Number of subjects: 591
Study 15302806 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT on
Number of subjects: 14
Study 15302806 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT off
Number of subjects: 14
Study 11256874 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (0.625 mg/d, Premarin) and medroxyprogesterone acetate (5 mg/d, Farlutal)
Number of subjects: 110
Study 11256874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 11907941 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen alone
Number of subjects: 875
Study 11907941 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus any progestin
Number of subjects: 875
Study 11907941 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous progestin regimen in combination with estrogen
Number of subjects: 875
Study 11907941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875
Study 8041979 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.005 mg/kg/po)
Number of subjects: 20
Study 8041979 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (0.03 mg/kg/po)
Number of subjects: 20
Study 2466670 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 10
Study 31758835 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical latanoprost gel twice daily for 12 weeks
Number of subjects: 31
Study 31758835 — intervention group
Group type: COMPARATOR
Intervention: Placebo with the same protocol
Number of subjects: 31
Study 29890802 — intervention group
Group type: EXPERIMENTAL
Intervention: Squeezing and clapping manipulation, once a week for 3 weeks
Number of subjects: 80
Study 29890802 — intervention group
Group type: COMPARATOR
Intervention: Pelvic bandage immobilization, not less than 8 hours per day for 3 weeks
Number of subjects: 80
Study 27898672 — intervention group
Group type: COMPARATOR
Intervention: Standard lifestyle advice alone (control group, n = 190)
Number of subjects: 569
Study 27898672 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk estimate (n = 189)
Number of subjects: 569
Study 27898672 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotypic risk estimate (n = 190)
Number of subjects: 569
Study 27898672 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk information (both genetic and phenotypic)
Number of subjects: 569
Study 24909348 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Training Curriculum (STC)
Number of subjects: 24
Study 24909348 — intervention group
Group type: COMPARATOR
Intervention: Self-Directed Learning (SDL)
Number of subjects: 24
Study 24450244 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus acidophilus and Bifidobacterium bifidum)
Number of subjects: 106
Study 24450244 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 106
Study 19924010 — intervention group
Group type: COMPARATOR
Intervention: CHO (6% carbohydrate supplement)
Number of subjects: 12
Study 19924010 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO/PRO H (4.5% carbohydrate plus 1.15% protein complex)
Number of subjects: 12
Study 19924010 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO/PRO L (3% carbohydrate plus 0.75% protein complex)
Number of subjects: 12
Study 19924010 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 12
Study 19924010 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO, CHO/PRO H, CHO/PRO L
Number of subjects: 12
Study 18392405 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-interferon
Number of subjects: 0
Study 15897719 — intervention group
Group type: EXPERIMENTAL
Intervention: Kudzu extract
Number of subjects: 0
Study 15897719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12093949 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA-supplemented formula
Number of subjects: 195
Study 12093949 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants
Number of subjects: 195
Study 10494491 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 40
Study 10494491 — intervention group
Group type: COMPARATOR
Intervention: 0.12% unoprostone
Number of subjects: 40
Study 10494491 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both treatments
Number of subjects: 40
Study 8943601 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and alfentanil
Number of subjects: 210
Study 8943601 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane and alfentanil
Number of subjects: 210
Study 8943601 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 210
Study 1826071 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydrochlorothiazide and triamterene
Number of subjects: 840
Study 1826071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 840
Study 1826071 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics alone or diuretics plus methyldopa
Number of subjects: 840
Study 7333741 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial A (3 days L, 3 days H)
Number of subjects: 0
Study 7333741 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial B (3 days M, 3 days H)
Number of subjects: 0
Study 7333741 — intervention group
Group type: COMPARATOR
Intervention: Trial C (6 days M)
Number of subjects: 0
Study 30938760 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (75 g)
Number of subjects: 37
Study 30938760 — intervention group
Group type: COMPARATOR
Intervention: Glucose (75 g)
Number of subjects: 37
Study 28778213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued Recall
Number of subjects: 36
Study 28778213 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproduction
Number of subjects: 36
Study 28778213 — intervention group
Group type: EXPERIMENTAL
Intervention: Restudy
Number of subjects: 36
Study 25751329 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose group (methotrexate 0.15 mg/kg weekly)
Number of subjects: 81
Study 25751329 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-weekly group (methotrexate 0.3 mg/kg every 2 weeks)
Number of subjects: 81
Study 25751329 — intervention group
Group type: COMPARATOR
Intervention: Control group (methotrexate stopped)
Number of subjects: 81
Study 24176390 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled aztreonam (AZLI)
Number of subjects: 0
Study 24176390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22902212 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (intraocular injections every 6 weeks for 12 months)
Number of subjects: 60
Study 22902212 — intervention group
Group type: COMPARATOR
Intervention: Sham injections (first 6 months), then Bevacizumab (intraocular injections every 6 weeks for 6 months)
Number of subjects: 60
Study 19397397 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Optical Access (DOA)
Number of subjects: 202
Study 19397397 — intervention group
Group type: COMPARATOR
Intervention: Open Entry (Hasson)
Number of subjects: 202
Study 17882731 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebeverine hydrochloride film-forming gel
Number of subjects: 0
Study 17882731 — intervention group
Group type: COMPARATOR
Intervention: Solcoseryl dental paste
Number of subjects: 0
Study 15333608 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude (Protocol I)
Number of subjects: 12
Study 15333608 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (Protocol II)
Number of subjects: 12
Study 15333608 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of physical exercise and high altitude (Protocol III)
Number of subjects: 12
Study 11821260 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization
Number of subjects: 0
Study 11821260 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 0
Study 11821260 — intervention group
Group type: COMPARATOR
Intervention: Myomectomy
Number of subjects: 0
Study 9475762 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily for four years)
Number of subjects: 3040
Study 9475762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3040
Study 8553300 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily inhaled budesonide (400 micrograms morning and bedtime)
Number of subjects: 40
Study 8553300 — intervention group
Group type: COMPARATOR
Intervention: Once daily inhaled budesonide (800 micrograms at bedtime)
Number of subjects: 40
Study 2096340 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon (1% sodium hyaluronate)
Number of subjects: 62
Study 2096340 — intervention group
Group type: COMPARATOR
Intervention: Viscoat (3% sodium hyaluronate and 4% chondroitin sulfate)
Number of subjects: 62
Study 436626 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg digoxin by mouth
Number of subjects: 0
Study 436626 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg beta-acetyldigoxin by mouth
Number of subjects: 0
Study 436626 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mg digoxin intravenously
Number of subjects: 0
Study 436626 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered digoxin
Number of subjects: 0
Study 436626 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered beta-acetyldigoxin
Number of subjects: 0
Study 436626 — intervention group
Group type: COMPARATOR
Intervention: Intravenously administered digoxin
Number of subjects: 0
Study 30644165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis of psychotic symptomatology
Number of subjects: 257
Study 29976285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg orally twice per day
Number of subjects: 0
Study 29976285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27569231 — intervention group
Group type: EXPERIMENTAL
Intervention: Parachute device implantation
Number of subjects: 31
Study 23881608 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term strength training (ST) program, 2 days/week for 6 weeks, consisting of leg press, knee extension, and knee flexion exercises
Number of subjects: 36
Study 23881608 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 36
Study 22290521 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized Power Balance performance mouth guard (PB MG)
Number of subjects: 50
Study 22290521 — intervention group
Group type: COMPARATOR
Intervention: Regular over the counter boil-and-bite mouth guard (Reg MG)
Number of subjects: 50
Study 22290521 — intervention group
Group type: COMPARATOR
Intervention: No mouth guard (No MG)
Number of subjects: 50
Study 18678703 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 31
Study 18678703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 17916465 — intervention group
Group type: EXPERIMENTAL
Intervention: sipuleucel‐T (Provenge®, Dendreon)
Number of subjects: 0
Study 17916465 — intervention group
Group type: COMPARATOR
Intervention: Other phase III studies
Number of subjects: 0
Study 15030966 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard amino acid solution (n = 10)
Number of subjects: 20
Study 15030966 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched chain amino acid enriched solution (n = 10)
Number of subjects: 20
Study 15030966 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 20
Study 11474314 — intervention group
Group type: EXPERIMENTAL
Intervention: Amtolmetin‐guacyl (AMG) 1200 mg for 2 days and 600 mg for 12 days
Number of subjects: 42
Study 11474314 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 40 mg for 2 days and 20 mg for 12 days
Number of subjects: 42
Study 11474314 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG
Number of subjects: 42
Study 11474314 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 42
Study 9502757 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital luminescence mammography
Number of subjects: 22
Study 9502757 — intervention group
Group type: COMPARATOR
Intervention: Conventional film-screen mammography
Number of subjects: 22
Study 9502757 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 22
Study 8037393 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 19
Study 8037393 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube
Number of subjects: 19
Study 2522625 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma albumin (PM)
Number of subjects: 80
Study 2522625 — intervention group
Group type: COMPARATOR
Intervention: Placental albumin (PC)
Number of subjects: 80
Study 30993452 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-Pal
Number of subjects: 0
Study 30993452 — intervention group
Group type: EXPERIMENTAL
Intervention: QLQ-C15-PAL
Number of subjects: 0
Study 30993452 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-G7
Number of subjects: 0
Study 30993452 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-Pal-14
Number of subjects: 0
Study 30993452 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-G
Number of subjects: 0
Study 30993452 — intervention group
Group type: EXPERIMENTAL
Intervention: QLQ-C15-PAL Pain
Number of subjects: 0
Study 30993452 — intervention group
Group type: EXPERIMENTAL
Intervention: QLQ-C15-PAL Fatigue
Number of subjects: 0
Study 30993452 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-Pal PalCare
Number of subjects: 0
Study 30993452 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-Pal TOI
Number of subjects: 0
Study 30993452 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-G Physical Wellbeing
Number of subjects: 0
Study 30993452 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-G Total
Number of subjects: 0
Study 31779786 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged nonculprit lesion PCI planned during the index hospitalization (median 1 day)
Number of subjects: 4041
Study 31779786 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged nonculprit lesion PCI planned after hospital discharge (median 23 days)
Number of subjects: 4041
Study 31779786 — intervention group
Group type: COMPARATOR
Intervention: Intended nonculprit lesion PCI within 45 days
Number of subjects: 4041
Study 31779786 — intervention group
Group type: COMPARATOR
Intervention: Intended nonculprit lesion PCI from 45 days to the end of follow-up
Number of subjects: 4041
Study 29231475 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) at Neiguan (PC 6) and Zusanli (ST 36) for 4 weeks, 20 minutes twice a day.
Number of subjects: 46
Study 29231475 — intervention group
Group type: COMPARATOR
Intervention: Conventional medication and nursing (Control group).
Number of subjects: 46
Study 24219497 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous plasma rich in growth factors (P-PRP) added to deproteinized bovine bone matrix (DBBM)
Number of subjects: 15
Study 24219497 — intervention group
Group type: COMPARATOR
Intervention: Deproteinized bovine bone matrix (DBBM)
Number of subjects: 15
Study 23532005 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) calls
Number of subjects: 268
Study 23532005 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR calls with informal caregiver involvement
Number of subjects: 268
Study 23532005 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR calls with patients reporting fair or poor health
Number of subjects: 268
Study 23532005 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR system usability
Number of subjects: 268
Study 23532005 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR calls' impact on health management
Number of subjects: 268
Study 21355447 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (levofloxacin 500 mg)
Number of subjects: 12
Study 21355447 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (levofloxacin 500 mg)
Number of subjects: 12
Study 18228523 — intervention group
Group type: EXPERIMENTAL
Intervention: PNL-2 staining
Number of subjects: 9
Study 18228523 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB-45 staining
Number of subjects: 9
Study 18228523 — intervention group
Group type: EXPERIMENTAL
Intervention: Melan-A staining
Number of subjects: 9
Study 18228523 — intervention group
Group type: EXPERIMENTAL
Intervention: S-100 staining
Number of subjects: 9
Study 18228523 — intervention group
Group type: EXPERIMENTAL
Intervention: MITF staining
Number of subjects: 9
Study 18228523 — intervention group
Group type: EXPERIMENTAL
Intervention: PNL-2 compared to Melan-A or MITF
Number of subjects: 9
Study 18228523 — intervention group
Group type: EXPERIMENTAL
Intervention: PNL-2
Number of subjects: 9
Study 16472797 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/d oral fluvastatin
Number of subjects: 60
Study 16472797 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/d oral fluvastatin
Number of subjects: 60
Study 16472797 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy (Control)
Number of subjects: 60
Study 12901033 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole suspension (20 mL of a suspension prepared from one crushed pantoprazole tablet and 840 mg of sodium bicarbonate solution)
Number of subjects: 12
Study 12901033 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole tablet (one enteric-coated 40-mg pantoprazole tablet by mouth with 240 mL of water)
Number of subjects: 12
Study 15945003 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic trabeculoplasty (PNT)
Number of subjects: 37
Study 10863496 — intervention group
Group type: EXPERIMENTAL
Intervention: CARIOSTAT caries activity test
Number of subjects: 0
Study 10863496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured microorganisms on MSB agar
Number of subjects: 0
Study 8766515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation under epidural analgesia
Number of subjects: 120
Study 8766515 — intervention group
Group type: COMPARATOR
Intervention: Supine position under epidural analgesia
Number of subjects: 120
Study 1835914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 100
Study 1835914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7318439 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ug EE (+ 125ug d‐norgestrel)
Number of subjects: 13
Study 7318439 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ug EE (+ 150ug d‐norgestrel)
Number of subjects: 13
Study 7318439 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic oral contraceptive users (110 participants)
Number of subjects: 13
Study 31661976 — intervention group
Group type: EXPERIMENTAL
Intervention: AEO (0.25 g/kg feed)
Number of subjects: 375
Study 31661976 — intervention group
Group type: EXPERIMENTAL
Intervention: MOS (2 g/kg feed)
Number of subjects: 375
Study 31661976 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO (0.15 g/kg feed)
Number of subjects: 375
Study 31661976 — intervention group
Group type: EXPERIMENTAL
Intervention: DEO (0.25 g/kg feed)
Number of subjects: 375
Study 31661976 — intervention group
Group type: COMPARATOR
Intervention: Control (basal diet)
Number of subjects: 375
Study 29065545 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based intervention
Number of subjects: 0
Study 29065545 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-based intervention
Number of subjects: 0
Study 29065545 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 25330083 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise at 80% of 1RM (HI)
Number of subjects: 24
Study 25330083 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise at 20% of 1RM (LI)
Number of subjects: 24
Study 25330083 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise at 20% of 1RM combined with partial blood flow restriction (LI + BFR)
Number of subjects: 24
Study 25330083 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 24837597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/5-fluorouracil 100/1000 combined with panitumumab 9 mg/kg (Arm 1)
Number of subjects: 20
Study 24837597 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/5-fluorouracil 100/1000 alone (Arm 2)
Number of subjects: 20
Study 22974389 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens‐based sensor (CLS) for monitoring of 24‐hr intraocular pressure (IOP) fluctuations
Number of subjects: 20